Zealand Pharma A/S (0NZU.IL)

621,50 +19,50 (+3,24%) Alla chiusura: 06:04PM BST

Zealand Pharma A/S

Sydmarken 11
SOeborg
Copenhagen 2860
Denmark
45 88 77 36 00
https://www.zealandpharma.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 236

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Adam Sinding Steensberg M.D.	Pres & CEO	8,09M	N/D	1974
Ms. Henriette Wennicke	EVP & CFO	2,81M	N/D	1983
Mr. Ivan Mourits Moller	Exec. VP & COO	N/D	N/D	1972
Mr. Mads Kronborg	Head of Investor Relations & Communication	N/D	N/D	N/D
Mr. Ravinder Chahil	Sr. VP & Gen. Counsel	N/D	N/D	1968
Ms. Christina Sonnenborg Bredal	Sr. VP and Global Head of People & Organization	N/D	N/D	1985
Dr. Jens Damsgaard Mikkelsen M.D.	Head of Molecular Pharmacology	N/D	N/D	N/D
Dr. Danilo Verge	Head of Global Medical Affairs	N/D	N/D	N/D
Dr. David M. Kendall M.D.	Sr. VP & Chief Medical Officer	N/D	N/D	1961
Lykke Romer	VP & Head of Fin. and Accounting	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in DKK.

Descrizione

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing both insulin and dasiglucagon. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Governance aziendale

L'ISS Governance QualityScore di Zealand Pharma A/S al 1 ottobre 2023 è 4. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 1; diritti degli azionisti: 1; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.